Free Trial
NASDAQ:CDXS

Codexis (CDXS) Stock Price, News & Analysis

Codexis logo
$3.14
-0.07 (-2.18%)
(As of 10/31/2024 ET)

About Codexis Stock (NASDAQ:CDXS)

Key Stats

Today's Range
$3.08
$3.26
50-Day Range
$2.62
$3.52
52-Week Range
$1.51
$4.91
Volume
468,166 shs
Average Volume
524,377 shs
Market Capitalization
$222.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.75
Consensus Rating
Moderate Buy

Company Overview

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Codexis Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
87th Percentile Overall Score

CDXS MarketRank™: 

Codexis scored higher than 87% of companies evaluated by MarketBeat, and ranked 165th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Codexis has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Codexis has only been the subject of 2 research reports in the past 90 days.

  • Read more about Codexis' stock forecast and price target.
  • Earnings Growth

    Earnings for Codexis are expected to decrease in the coming year, from ($0.75) to ($0.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Codexis is -2.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Codexis is -2.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Codexis has a P/B Ratio of 2.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Codexis' valuation and earnings.
  • Percentage of Shares Shorted

    2.82% of the outstanding shares of Codexis have been sold short.
  • Short Interest Ratio / Days to Cover

    Codexis has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Codexis has recently decreased by 11.50%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Codexis does not currently pay a dividend.

  • Dividend Growth

    Codexis does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.82% of the outstanding shares of Codexis have been sold short.
  • Short Interest Ratio / Days to Cover

    Codexis has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Codexis has recently decreased by 11.50%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Codexis has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Codexis this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Codexis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,514,910.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 2.10% of the stock of Codexis is held by insiders.

  • Percentage Held by Institutions

    78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Codexis' insider trading history.
Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

CDXS Stock News Headlines

Codexis Reports Third Quarter 2024 Financial Results
Unveiled: NVIDIA’s "Secret Royalty" Program
Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?
Codexis (CDXS) to Release Quarterly Earnings on Thursday
Codexis announces employment inducement grants
Codexis Announces New Employment Inducement Grants
See More Headlines

CDXS Stock Analysis - Frequently Asked Questions

Codexis' stock was trading at $3.05 at the beginning of the year. Since then, CDXS stock has increased by 3.0% and is now trading at $3.14.
View the best growth stocks for 2024 here
.

Codexis, Inc. (NASDAQ:CDXS) posted its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.06. The biotechnology company had revenue of $7.98 million for the quarter, compared to analysts' expectations of $7.64 million. Codexis had a negative trailing twelve-month return on equity of 64.06% and a negative net margin of 125.41%.

Top institutional shareholders of Codexis include Assenagon Asset Management S.A. (1.56%), abrdn plc (1.13%), Private Advisor Group LLC (0.39%) and Perkins Capital Management Inc. (0.23%). Insiders that own company stock include Opaleye Management Inc, John J Nicols, Byron L Dorgan, Sriram Ryali, Kevin Norrett, Margaret Nell Fitzgerald, Dennis P Wolf and Patrick Y Yang.
View institutional ownership trends
.

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Codexis investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Walt Disney (DIS) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
8/08/2024
Today
10/31/2024
Next Earnings (Confirmed)
10/31/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Industrial organic chemicals
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CDXS
CUSIP
19200510
Employees
250
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.75
High Stock Price Target
$11.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+178.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-76,240,000.00
Net Margins
-125.41%
Pretax Margin
-125.30%

Debt

Sales & Book Value

Annual Sales
$60.89 million
Book Value
$1.24 per share

Miscellaneous

Free Float
69,438,000
Market Cap
$222.71 million
Optionable
Optionable
Beta
2.08
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (NASDAQ:CDXS) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners